<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04769362</url>
  </required_header>
  <id_info>
    <org_study_id>SMC202010176</org_study_id>
    <nct_id>NCT04769362</nct_id>
  </id_info>
  <brief_title>Long-term Beta-blocker Therapy After Acute Myocardial Infarction</brief_title>
  <acronym>SMART-DECISION</acronym>
  <official_title>Discontinuation of β-blocker Therapy in Stabilized Patients After Acute Myocardial Infarction: A Multicenter Randomized Noninferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyung Hee University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sejong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Changwon Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint Vincent's Hospital, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Presbyterian medical center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonkwang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University Seoul Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jeju National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chosun University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine whether discontinuation of β-blocker after at least 1&#xD;
      year of β-blocker therapy is noninferior to continuation of β-blocker in patients without&#xD;
      heart failure (HF) or left ventricular systolic dysfunction after acute myocardial infarction&#xD;
      (AMI).&#xD;
&#xD;
      Prospective, open-label, randomized, multicenter, noninferiority trial to determine whether&#xD;
      discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to&#xD;
      continuation of β-blocker in patients without HF or left ventricular systolic dysfunction&#xD;
      after AMI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      β-blockers have anti-ischemic, anti-arrhythmic, and anti-adrenergic properties. In order to&#xD;
      reduce cardiovascular mortality and morbidity, current major guidelines recommend that oral&#xD;
      treatment of β-blockers should be continued during and after hospitalization in patients with&#xD;
      acute myocardial infarction (AMI) and without contraindications to β-blocker use.&#xD;
&#xD;
      A clinically important but difficult decision on β-blocker therapy after AMI is to determine&#xD;
      the duration of β-blocker therapy after discharge in patients without heart failure (HF) or&#xD;
      left ventricular systolic dysfunction. Previous studies for long-term β-blocker therapy after&#xD;
      AMI were inadequate to derive definite conclusion because of small sample size and potential&#xD;
      selection bias.&#xD;
&#xD;
      Therefore, the SMART-DECISION trial will investigate whether discontinuation of β-blocker&#xD;
      after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in&#xD;
      patients without HF or left ventricular systolic dysfunction after AMI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2021</start_date>
  <completion_date type="Anticipated">March 20, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>at 2 years</time_frame>
    <description>a composite of all-cause death, myocardial infarction, hospitalization for heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any hospitalization</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for acute coronary syndrome</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death or myocardial infarction</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death or myocardial infarction</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction or hospitalization for heart failure</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>at 2 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction or any revascularization</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death, myocardial infarction, or any revascularization</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle ejection fraction</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal pro-brain natriuretic peptide (NT-proBNP)</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical cost</measure>
    <time_frame>at 2 years</time_frame>
    <description>The medical expenses related to heart problems during the follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS 29</measure>
    <time_frame>at 2 years</time_frame>
    <description>PROMIS 29 is composed of a total of 29 questions, and questions are composed of domains for physical function, anxiety, depression, sleep, social function, participation availability, and pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects related with β-blocker</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2540</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>β-blocker discontinuation arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Discontinuation of β-blocker therapy after at least 1 year of β-blocker therapy after acute myocardial infarction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>β-blocker maintenance arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continuation of β-blocker therapy after acute myocardial infarction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Discontinuation of β-blocker</intervention_name>
    <description>Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction</description>
    <arm_group_label>β-blocker discontinuation arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be at least 19 years of age.&#xD;
&#xD;
          -  Subject who have been continuing β-blocker therapy for at least 1 year after acute&#xD;
             myocardial infarction regardless of the time of diagnosis&#xD;
&#xD;
          -  Subject is able to verbally confirm understandings of risks and benefits of this&#xD;
             trial, and he/she or his/her legally authorized representative provides written&#xD;
             informed consent prior to any study related procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject whose left ventricle ejection fraction was less than 40% from echocardiography&#xD;
             performed after acute myocardial infarction or who have never received&#xD;
             echocardiography.&#xD;
&#xD;
          -  Treatment history of heart failure&#xD;
&#xD;
          -  Contraindication to β-blocker therapy (history of symptomatic bronchial asthma or&#xD;
             chronic obstructive pulmonary disease, 2nd or 3rd degree AV block, cardiac pacemaker&#xD;
             implantation, or other cases where β-blocker cannot be used under the judgment of the&#xD;
             clinician)&#xD;
&#xD;
          -  Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment).&#xD;
&#xD;
          -  History of atrial fibrillation&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Severe renal dysfunction (creatinine clearance &lt; 30 ml/min/1.73 m2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Yong Hahn, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joo-Yong Hahn, MD,PhD</last_name>
    <phone>82-2-3410-6653</phone>
    <email>jyhahn@skku.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyung Ui Hwang</last_name>
    <phone>82-70-7014-4155</phone>
    <email>ku.hwang@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 21, 2021</last_update_submitted>
  <last_update_submitted_qc>February 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joo-Yong Hahn</investigator_full_name>
    <investigator_title>MD, PhD, Division of Cardiology, Department of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

